# Trade Mark Journal No.2026/030 24 July 2026

## WO0000001927257 (5)

Office of origin: United States of America

Date of International Registration:7 May 2026
Date of designation in the UK: 7 May 2026

International priority date claimed: 20 November 2025 (United States of America) (99507779)

Class 5
  Therapeutic pharmaceuticals for the treatment of autoimmune diseases; therapeutic pharmaceuticals and cell therapy products in the nature of cells for medical or clinical use for the treatment of autoimmune disease; cell therapy products, namely, genetically engineered immune cells for medical or clinical use for the treatment of autoimmune disease; pharmaceutical preparations and substances for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders.

Kyverna Therapeutics, Inc.

Representative: Lisa Greenwald-Swire Fish & Richardson P.C., P.O. Box 1022, Minneapolis MN 55440-1022, UNITED STATES OF AMERICA